Rituxan

Latest stories

4d
Business Wire
Global & USA Cancer Immunotherapy Market Analysis to 2020 - Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the Top Five Cancer Drugsbe the backbone of cancer treatments in 60% of cancer types. It is forecast th
Global & USA Cancer Immunotherapy Market Analysis to 2020 - Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the Top Five Cancer Drugs
Business Wire / Posted 4 days ago
be the backbone of cancer treatments in 60% of cancer types. It is forecast that by 2020, Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the top five cancer drugs. A single drug, Bristol-Myers Squibb's Yervoy, for example has earned... Read more
9d
EuroNews
Unilever and Roche results better than expectedbecause of low interest rates. Roche, the world’s biggest maker of cancer drug
Unilever and Roche results better than expected
EuroNews / Posted 9 days ago
because of low interest rates. Roche, the world’s biggest maker of cancer drugs, saw sales of its three major established cancer medicines — Herceptin, Avastin and Rituxan with more than 6 billion francs in annual sales each — continue t... Read more
12d
Swissinfo
Roche Blood Cancer Drug Fails to Show Significant ImprovementRoche Holding AG said its blood cancer medicine Gazyva failed to show a signifi
Roche Blood Cancer Drug Fails to Show Significant Improvement
Swissinfo / Posted 12 days ago
Roche Holding AG said its blood cancer medicine Gazyva failed to show a significant improvement over its best-seller Rituxan, a setback in efforts to defend the ageing drug blockbuster against copycats. In an advanced study called Goya,... Read more
12d
Business Wire
Genentech Provides Update on Phase III Study of Gazyva® in People With Previously Untreated Diffuse Large B-Cell Lymphomaendpoint of significantly reducing the risk of disease worsening or death (prog
Genentech Provides Update on Phase III Study of Gazyva® in People With Previously Untreated Diffuse Large B-Cell Lymphoma
Business Wire / Posted 12 days ago
endpoint of significantly reducing the risk of disease worsening or death (progression-free survival; PFS) compared to Rituxan® (rituximab) plus CHOP chemotherapy (R-CHOP). Adverse events with Gazyva and Rituxan were consistent with those seen... Read more
28d
Swissinfo
Roche to cut 350 IT jobsdrugs rose 4% to CHF12.4 billion ($12.87 billion). Sales of its "big three" can
Roche to cut 350 IT jobs
Swissinfo / Posted 28 days ago
drugs rose 4% to CHF12.4 billion ($12.87 billion). Sales of its "big three" cancer medicines - Herceptin, Avastin and Rituxan that together account for more than a third of revenue - continued to climb. The pharma giant aims to launch eight... Read more
29d
FOX Business
This $6.7 Billion Drug Just Keeps GrowingCelgene is testing Revlimid as a maintenance therapy for patients who have succ
This $6.7 Billion Drug Just Keeps Growing
FOX Business / Posted 29 days ago
Celgene is testing Revlimid as a maintenance therapy for patients who have successfully completed a treatment of Roche's Rituxan plus chemotherapy. Data from REMARC and another trial, CONTINUUM, testing Revlimid as a maintenance therapy for... Read more
29d
FOX Business
This $6.7 Billion Drug Just Keeps GrowingCelgene is testing Revlimid as a maintenance therapy for patients who have succ
This $6.7 Billion Drug Just Keeps Growing
FOX Business / Posted 29 days ago
Celgene is testing Revlimid as a maintenance therapy for patients who have successfully completed a treatment of Roche's Rituxan plus chemotherapy. Data from REMARC and another trial, CONTINUUM, testing Revlimid as a maintenance therapy for... Read more

People in this news